Paul J Clark1,2,3, Katherine A Stuart2, Barbara A Leggett3,4, Darrell H Crawford3, Peter Boyd5, Jonathan Fawcett3,6, David C Whiteman1,3, Peter D Baade3,7. 1. Cancer Control Unit, QIMR-Berghofer Medical Research Institute, Brisbane, Qld, Australia. 2. Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Qld, Australia. 3. School of Medicine, University of Queensland, Brisbane, Qld, Australia. 4. Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia. 5. Cairns Base Hospital, Cairns, Qld, Australia. 6. Hepato-Pancreato-Biliary Surgery Unit, Princess Alexandra Hospital, Brisbane, Qld, Australia. 7. Epidemiology, Cancer Council Queensland, Brisbane, Qld, Australia.
Abstract
BACKGROUND & AIMS: Incidence and mortality of hepatocellular carcinoma (HCC) is increasing globally, but varies between countries and regions. To target scarce resources to most need, clinical services must be informed by regional epidemiology. Using population-based data, we sought to document the incidence and mortality of HCC in Queensland, Australia, a state occupying a vast land area with diverse at-risk subpopulations. METHODS: Using population-based data from 1996 to 2011, the age-standardised incidence rate (ASR), annual percentage change (APC) and survival of HCC in Queensland were assessed with negative binomial regression, Kaplan-Meier and Cox survival analysis. Spatial patterns of HCC incidence and survival and relevant predictors were mapped. RESULTS: Thousand six hundred and twenty HCCs were diagnosed during this study period, with an overall ASR of 2.00-cases/1000 population. ASR increased by 3.5% per year, (95% CI: 2.1 to 5.0), P < 0.001) among males to 5.6/100,000 in 2011 and a non-significant increase of 2.6% per year, (95% CI = -0.7 to 6.0), P = 0.111) among females to 1.6/100,000 in 2011. Higher incidence was associated with male gender, older age, major city residence and proportionally higher area Indigenous population. Thousand and two hundred and eighty-seven patients died. Median survival was approximately 10 months. Five-year survival improved from 18% in 1996-2000 to 24% in 2006-2011 (P < 0.001). Poorer survival was associated with older age, less recent period of diagnosis, lower hepatitis B prevalence in country of origin and greater area-level social disadvantage. CONCLUSIONS: Over this study period, HCC incidence increased significantly. HCC survival improved but remains poor. Social determinants are critical to HCC epidemiology.
BACKGROUND & AIMS: Incidence and mortality of hepatocellular carcinoma (HCC) is increasing globally, but varies between countries and regions. To target scarce resources to most need, clinical services must be informed by regional epidemiology. Using population-based data, we sought to document the incidence and mortality of HCC in Queensland, Australia, a state occupying a vast land area with diverse at-risk subpopulations. METHODS: Using population-based data from 1996 to 2011, the age-standardised incidence rate (ASR), annual percentage change (APC) and survival of HCC in Queensland were assessed with negative binomial regression, Kaplan-Meier and Cox survival analysis. Spatial patterns of HCC incidence and survival and relevant predictors were mapped. RESULTS: Thousand six hundred and twenty HCCs were diagnosed during this study period, with an overall ASR of 2.00-cases/1000 population. ASR increased by 3.5% per year, (95% CI: 2.1 to 5.0), P < 0.001) among males to 5.6/100,000 in 2011 and a non-significant increase of 2.6% per year, (95% CI = -0.7 to 6.0), P = 0.111) among females to 1.6/100,000 in 2011. Higher incidence was associated with male gender, older age, major city residence and proportionally higher area Indigenous population. Thousand and two hundred and eighty-seven patients died. Median survival was approximately 10 months. Five-year survival improved from 18% in 1996-2000 to 24% in 2006-2011 (P < 0.001). Poorer survival was associated with older age, less recent period of diagnosis, lower hepatitis B prevalence in country of origin and greater area-level social disadvantage. CONCLUSIONS: Over this study period, HCC incidence increased significantly. HCC survival improved but remains poor. Social determinants are critical to HCC epidemiology.
Authors: Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Gastroenterology Date: 2016-11-05 Impact factor: 22.682
Authors: Cortlandt M Sellers; Johannes Uhlig; Johannes M Ludwig; Tamar Taddei; Stacey M Stein; Joseph K Lim; Hyun S Kim Journal: Cancer Med Date: 2019-08-22 Impact factor: 4.452
Authors: Patricia C Valery; Christina M Bernardes; Katherine A Stuart; Gunter F Hartel; Steven M McPhail; Richard Skoien; Tony Rahman; Paul J Clark; Leigh U Horsfall; Kelly L Hayward; Rohit Gupta; Elizabeth E Powell Journal: Patient Prefer Adherence Date: 2020-03-18 Impact factor: 2.711
Authors: Alan J Wigg; Sumudu K Narayana; Gunter Hartel; Linda Medlin; Greg Pratt; Elizabeth E Powell; Paul Clark; Jane Davies; Kirsty Campbell; Maree Toombs; Michael Larkin; Patricia C Valery Journal: EClinicalMedicine Date: 2021-06-07
Authors: Hanna E Tervonen; Richard Walton; Hui You; Deborah Baker; David Roder; David Currow; Sanchia Aranda Journal: BMC Cancer Date: 2017-06-02 Impact factor: 4.430